{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-025828","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.662760+00:00","generated_at":"2026-05-24T09:57:39.906480+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cognition Therapeutics reports 2024 net loss of $34M; highlights positive Phase 2 data for zervimesine","bullets":["Cash and equivalents $25.0M at Dec 31 2024; $50.0M in NIA grant funds remaining.","Net loss $34.0M ($0.86 per share) vs $25.8M ($0.86) in 2023; R&D expense $41.7M.","Phase 2 SHIMMER DLB study: up to 91% slowing vs placebo across behavior, cognition, function, movement.","Phase 2 SHINE Alzheimer's subgroup with lower p-tau217 showed near-total preservation of cognition.","Plans to request end-of-Phase 2 FDA meetings in Q2 2025 for DLB and Alzheimer's; cash runway into Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-025828","json":"https://secwatch.observer/filing/0001104659-25-025828.json","markdown":"https://secwatch.observer/filing/0001104659-25-025828.md","text":"https://secwatch.observer/filing/0001104659-25-025828.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/0001104659-25-025828-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925025828/tm259712d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T09:57:39.906480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}